These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

212 related articles for article (PubMed ID: 37522686)

  • 21. Comparative of the Effectiveness and Safety of Biological Agents, Tofacitinib, and Fecal Microbiota Transplantation in Ulcerative Colitis: Systematic Review and Network Meta-Analysis.
    Zhou HY; Guo B; Lufumpa E; Li XM; Chen LH; Meng X; Li BZ
    Immunol Invest; 2021 May; 50(4):323-337. PubMed ID: 32009472
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Systematic review with meta-analysis: comparative efficacy of biologics for induction and maintenance of mucosal healing in Crohn's disease and ulcerative colitis controlled trials.
    Cholapranee A; Hazlewood GS; Kaplan GG; Peyrin-Biroulet L; Ananthakrishnan AN
    Aliment Pharmacol Ther; 2017 May; 45(10):1291-1302. PubMed ID: 28326566
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Systematic review and network meta-analysis: first- and second-line biologic therapies for moderate-severe Crohn's disease.
    Singh S; Fumery M; Sandborn WJ; Murad MH
    Aliment Pharmacol Ther; 2018 Aug; 48(4):394-409. PubMed ID: 29920733
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Efficacy and safety of biologic agents and tofacitinib in moderate-to-severe ulcerative colitis: A systematic overview of meta-analyses.
    Pantavou K; Yiallourou AI; Piovani D; Evripidou D; Danese S; Peyrin-Biroulet L; Bonovas S; Nikolopoulos GK
    United European Gastroenterol J; 2019 Dec; 7(10):1285-1303. PubMed ID: 31839954
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Network meta-analysis on efficacy and safety of different Janus kinase inhibitors for ulcerative colitis.
    Li Y; Yao C; Xiong Q; Xie F; Luo L; Li T; Feng P
    J Clin Pharm Ther; 2022 Jul; 47(7):851-859. PubMed ID: 35253941
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Comparative efficacy of golimumab, infliximab, and adalimumab for moderately to severely active ulcerative colitis: a network meta-analysis accounting for differences in trial designs.
    Thorlund K; Druyts E; Toor K; Mills EJ
    Expert Rev Gastroenterol Hepatol; 2015 May; 9(5):693-700. PubMed ID: 25763862
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Comparative efficacy and safety of biologic therapies for moderate-to-severe Crohn's disease: a systematic review and network meta-analysis.
    Singh S; Murad MH; Fumery M; Sedano R; Jairath V; Panaccione R; Sandborn WJ; Ma C
    Lancet Gastroenterol Hepatol; 2021 Dec; 6(12):1002-1014. PubMed ID: 34688373
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The impact of biological interventions for ulcerative colitis on health-related quality of life.
    LeBlanc K; Mosli MH; Parker CE; MacDonald JK
    Cochrane Database Syst Rev; 2015 Sep; 2015(9):CD008655. PubMed ID: 26393522
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Comparative Speed of Early Symptomatic Remission With Advanced Therapies for Moderate-to-Severe Ulcerative Colitis: A Systematic Review and Network Meta-Analysis.
    Ahuja D; Murad MH; Ma C; Jairath V; Singh S
    Am J Gastroenterol; 2023 Sep; 118(9):1618-1625. PubMed ID: 36976548
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Drug utilization of biologic therapy in Crohn's disease and ulcerative colitis: a population-based Danish cohort study 2015-2020.
    Jensen KJ; Jensen CB; Wennerström C; Burisch J; Petersen J
    Scand J Gastroenterol; 2023 Jul; 58(7):726-736. PubMed ID: 36802972
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Use of biologics and small molecule drugs for the management of moderate to severe ulcerative colitis: IG-IBD technical review based on the GRADE methodology.
    Bonovas S; Pansieri C; Piovani D; Macaluso FS; Orlando A; Festa S; Papi C; Pugliese D; Armuzzi A
    Dig Liver Dis; 2022 Apr; 54(4):428-439. PubMed ID: 35183439
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Biologics or tofacitinib for people with rheumatoid arthritis naive to methotrexate: a systematic review and network meta-analysis.
    Singh JA; Hossain A; Mudano AS; Tanjong Ghogomu E; Suarez-Almazor ME; Buchbinder R; Maxwell LJ; Tugwell P; Wells GA
    Cochrane Database Syst Rev; 2017 May; 5(5):CD012657. PubMed ID: 28481462
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Biologics or tofacitinib for people with rheumatoid arthritis unsuccessfully treated with biologics: a systematic review and network meta-analysis.
    Singh JA; Hossain A; Tanjong Ghogomu E; Mudano AS; Maxwell LJ; Buchbinder R; Lopez-Olivo MA; Suarez-Almazor ME; Tugwell P; Wells GA
    Cochrane Database Syst Rev; 2017 Mar; 3(3):CD012591. PubMed ID: 28282491
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Treatment sequence network meta-analysis in Crohn's disease: a methodological case study.
    Varu A; Wilson FR; Dyrda P; Hazel M; Hutton B; Cameron C
    Curr Med Res Opin; 2019 May; 35(5):733-756. PubMed ID: 30727745
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Efficacy of biologic therapies for biologic-naïve Japanese patients with moderately to severely active ulcerative colitis: a network meta-analysis.
    Hibi T; Kamae I; Pinton P; Ursos L; Iwakiri R; Hather G; Patel H
    Intest Res; 2021 Jan; 19(1):53-61. PubMed ID: 32312035
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Systematic review with network meta-analysis: the impact of medical interventions for moderate-to-severe ulcerative colitis on health-related quality of life.
    Paschos P; Katsoula A; Salanti G; Giouleme O; Athanasiadou E; Tsapas A
    Aliment Pharmacol Ther; 2018 Dec; 48(11-12):1174-1185. PubMed ID: 30378141
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Meta-analysis: Real-world effectiveness and safety of ustekinumab in patients with ulcerative colitis.
    Taxonera C; Olivares D; López-García ON; Alba C
    Aliment Pharmacol Ther; 2023 Mar; 57(6):610-619. PubMed ID: 36645145
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Matching-Adjusted Indirect Comparisons of Filgotinib vs Vedolizumab, Tofacitinib, and Ustekinumab for Moderately to Severely Active Ulcerative Colitis.
    Lu X; Zhou ZY; Xin Y; Wang MJ; Gray E; Jairath V; Lindsay JO
    Inflamm Bowel Dis; 2024 Jan; 30(1):64-77. PubMed ID: 36946138
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Infliximab is superior to other biological agents for treatment of active ulcerative colitis: A meta-analysis.
    Mei WQ; Hu HZ; Liu Y; Li ZC; Wang WG
    World J Gastroenterol; 2015 May; 21(19):6044-51. PubMed ID: 26019471
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Cost-Effectiveness Analysis of Vedolizumab Compared with Other Biologics in Anti-TNF-Naïve Patients with Moderate-to-Severe Ulcerative Colitis in Japan.
    Hernandez L; Kuwabara H; Shah A; Yamabe K; Burnett H; Fahrbach K; Koufopoulou M; Iwakiri R
    Pharmacoeconomics; 2020 Jan; 38(1):69-84. PubMed ID: 31552601
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.